The tolerability of a combined hepatitis A and typhoid vaccine in children aged 2-16 years: an observational study

Lau, Colleen L., Streeton, Catherine L., David, Michael C., Sly, Peter D. and Mills, Deborah J. (2016) The tolerability of a combined hepatitis A and typhoid vaccine in children aged 2-16 years: an observational study. Journal of Travel Medicine, 23 2: 1-8. doi:10.1093/jtm/tav023


Author Lau, Colleen L.
Streeton, Catherine L.
David, Michael C.
Sly, Peter D.
Mills, Deborah J.
Title The tolerability of a combined hepatitis A and typhoid vaccine in children aged 2-16 years: an observational study
Journal name Journal of Travel Medicine   Check publisher's open access policy
ISSN 1195-1982
1708-8305
Publication date 2016-02
Year available 2016
Sub-type Article (original research)
DOI 10.1093/jtm/tav023
Open Access Status Not Open Access
Volume 23
Issue 2
Start page 1
End page 8
Total pages 8
Place of publication Cary, NC United States
Publisher Oxford University Press
Collection year 2017
Language eng
Formatted abstract
Background: Combined hepatitis A and typhoid vaccines have been widely used globally and proven to be safe, well tolerated and efficacious in adults. The combined hepatitis A and typhoid vaccine (Vivaxim) available in Australia is licenced for use from age 16 years but the monovalent components are approved for use from age 2 years. Advantages of a single injection have led to widespread ‘off-label’ use of Vivaxim in children. This study aimed to investigate the tolerability of Vivaxim in children aged 2–16 years.

Methods: A prospective observational study was conducted at Travel Medicine Alliance clinics across Australia. Children who required vaccination for both hepatitis A and typhoid were offered the option of receiving Vivaxim. Parents were contacted 3 days post-vaccination and asked to respond to a questionnaire on adverse events following immunization (AEFIs). Reactions to Vivaxim were compared with reported reactions to the monovalent vaccines.

Results: Our study included 425 children who received Vivaxim, including 189 (44.5%) who received other vaccines on the same day. No serious AEFIs were reported, and 26.8% did not experience any side effects. In children who did not receive other vaccines in the same arm as Vivaxim (n = 325), most common local reactions were sore arm (70.5%), redness (16.0%) and swelling (11.1%). Reports of local AEFIs in our subjects was significantly more common than those reported for the individual monovalent vaccines. In children who did not receive other vaccines on the same day (n = 236), the most common systemic reactions were tiredness/lethargy/malaise (5.9%), headache (4.2%), fever (3.4%) and sore muscles and joints (3.4%). Fever was more common in children aged <6 years. Less than 5% of children reported missing school, sport or other regular activities.

Conclusions: Vivaxim was well tolerated in children aged 2–16 years. Parents should be advised about AEFIs to Vivaxim so that they can make informed decisions about vaccination options.
Keyword Vaccine
Immunization
Hepatitis A
Typhoid
Vivaxim
Children
Vaccination
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: HERDC Pre-Audit
Admin only - CHRC
Child Health Research Centre Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Google Scholar Search Google Scholar
Created: Sun, 22 May 2016, 00:20:27 EST by System User on behalf of Child Health Research Centre